In 2013, FDA approved EGFR-TKI erlotinib (Tarceva) for first-line treatment of metastatic NSCLC patients whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [5]. Here, EGFR is linked to non-small cell lung carcinoma.